Biogen and Denali announced that their Phase 2b LUMA study of BIIB122 (DNL151) in early-stage Parkinson's disease did not meet its primary or secondary endpoints, showing no slowing of disease progression compared to placebo. Despite good safety and biomarker results, the companies will discontinue BIIB122 development for idiopathic Parkinson's disease. Denali will continue a separate Phase 2a BEACON study targeting Parkinson's patients with a specific LRRK2 genetic variant, with results expected in early 2027. This decision highlights the challenges in developing effective Parkinson's treatments and the ongoing research into LRRK2 as a therapeutic target.
Biogen Inc. announced the appointment of Michael J. Parini as its new Chief Legal Officer, effective August 3, 2026. Parini brings over 20 years of legal and strategic leadership in the biopharmaceutical industry, having held senior roles at Spur The...
The LEADER study found that nearly 83% of early Alzheimer's patients remained stable or improved while on LEQEMBI treatment for an average of 17 months, consistent across demographics and genetic profiles. LEQEMBI targets amyloid beta to slow cogniti...
Biogen announced positive Phase 2 results for diranersen, an antisense therapy targeting tau protein in early Alzheimer's disease. The study showed meaningful clinical benefits, including slowing cognitive decline by up to 50% on some measures, and r...
The FDA has approved LEQEMBI IQLIK, a once-weekly subcutaneous injection for initiating treatment of early Alzheimer's disease, allowing at-home dosing. This new form offers a convenient alternative to intravenous infusions, providing flexibility for...
Biogen's stock received an upgrade as investors anticipate the company's upcoming announcement of detailed data from its Phase 2 study on an experimental Alzheimer's drug. This data release is significant because it could impact the future of Alzheim...
